FC
UTHR icon

FCA Corp’s United Therapeutics UTHR Stock Holding History

FCA Corp’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,750
Closed -$219K – 175
2019
Q3 		$219K Hold
2,750
– – 0.08% 144
2019
Q2 		$215K Hold
2,750
– – 0.08% 150
2019
Q1 		$323K Hold
2,750
– – 0.13% 109
2018
Q4 		$299K Hold
2,750
– – 0.13% 106
2018
Q3 		$352K Hold
2,750
– – 0.13% 110
2018
Q2 		$311K Hold
2,750
– – 0.12% 114
2018
Q1 		$309K Hold
2,750
– – 0.13% 110
2017
Q4 		$407K Hold
2,750
– – 0.16% 98
2017
Q3 		$322K Hold
2,750
– – 0.13% 107
2017
Q2 		$357K Hold
2,750
– – 0.16% 97
2017
Q1 		$372K Hold
2,750
– – 0.18% 87
2016
Q4 		$394K Hold
2,750
– – 0.2% 81
2016
Q3 		$325K Hold
2,750
– – 0.17% 87
2016
Q2 		$291K Buy
2,750
+750
+38% +$83.7K 0.15% 105
2016
Q1 		$223K Buy
+2,000
New +$253K 0.12% 123

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCA Corp's UTHR Position: Q4 2019 in Review

FCA Corp sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 2,750 shares — an estimated $219K sold.

FCA Corp first reported a position in UTHR in Q1 2016 and held it in 15 quarters. The position peaked at $407K in Q4 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

  • FCA Corp reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
  • FCA Corp sold 2,750 United Therapeutics shares in Q4 2019, an estimated $219K.
  • FCA Corp first reported a position in United Therapeutics in Q1 2016 and held it in 15 quarters.
  • FCA Corp's United Therapeutics position peaked at $407K in Q4 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on FCA Corp's 13F filing for Q4 2019, filed 11 Feb 2020.